• Homepage
• About us
• Our Partners
• Research database
• Workshops
• Newsletters and resources
• Videos and Animations
• International Conferences
• Funding opportunities
• Search

My group focuses on the development of oligonucleotide-based cancer immunotherapies. We demonstrated the feasibility of using TLR9 agonists, CpG DNA, for targeted delivery of therapeutic STAT3 siRNA or ASO to immune cells infiltrating solid tumors, such as glioma. The first two generations of CpG-STAT3 inhibitors are undergoing safety/tolerability studies assisting IND filing for therapy of human B cell lymphoma and malignant glioma. I am an active member of the Oligonucleotide Therapeutics Society (Advisory Council Member), ASGCT and AACR.

Existing collaborations relevant to drug delivery

N/A

Publications relevant to drug delivery

Herrmann A, Cherryholmes G, Schroeder A, Phallen J, Alizadeh D, Xin H, Wang T, Lee H, Lahtz C, Swiderski P, Armstrong B, Kowolik C, Gallia GL, Lim M, Brown CE, Badie B, Forman SJ, Kortylewski M, Jove R, Yu H. (2014) TLR9 is critical for Glioma Stem Cell Maintenance and Targeting. Cancer Res., 74, 5218-5228. 

Gao C, Kozlowska A, Nechaev S, Li H, Zhang Q, Hossain DMS, Kowolik CM, Chu P, Swiderski P, Diamond DJ, Pal SK, Raubitschek A, Kortylewski M. (2013) TLR9 signaling in the tumor microenvironment initiates cancer recurrence after radiation therapy. Cancer Res., 73, 7211-7221.

Zhang Q, Hossain DMS, Nechaev S, Kozlowska A, Zhang W, Liu Y, Kowolik CM, Swiderski P, Rossi JJ, Forman S, Yu H, Kortylewski M. (2013) TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo. Blood, 21, 1304-1315.